Exploring the Unexplored to Give Patients Better Options
No patient with cancer should ever run out of options. At Verastem Oncology, we’re working every day to make sure they don’t. By embracing the power of external partnerships and collaboration, we’re putting our collective knowledge and expertise to work to deliver novel treatment approaches that address areas of high unmet need in RAS pathway-driven cancers. Patients desperately need better treatment options. We’re fighting to give them more possibilities—and more hope. Watch the video to see how customized combinations of avutometinib (VS-6766), a unique dual RAF/MEK inhibitor, including a combination with defactinib, a selective FAK inhibitor, have the potential to greatly expand the number of effective treatments options for these patients.
Verastem Oncology is relentlessly pursuing RAS-targeted treatment combinations with avutometinib (VS-6766).
Access Verastem Oncology’s latest posters, presentations, and publications.
Learn about avutometinib (VS-6766), an investigational backbone of therapy in RAS pathway-driven cancers.
Blocking the RAS Signaling Pathway
We are working to realize the full therapeutic potential of targeting the RAS pathway.